Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn

 In the aftermath of the Food and Drug Administration’s Aduhelm debacle, the agency’s neuroscience chief Billy Dunn has another controversial approval decision to make. It will once again test his willingness to apply the FDA’s doctrine of “regulatory flexibility” to a medicine with less-than-convincing clinical data.

https://www.statnews.com/2023/02/17/reata-billy-dunn/